1. Orphan Drug Designation (ODD) from the FDA for both Glioblastoma and multiple types of Gliomas.

2. Finalizing discussions with the NIH on conducting Phase II Clinical Trials in GBM.

3. Clinical trial based on basic research performed by the NIH, by Purdue University, by the Robert Preston Tisch Brain Tumor Center at Duke University, and by Gibson Oncology.

4. Multiple Phase I FDA clinical trials completed by the National Cancer Institute.

Gibson Oncology will release more specific information when granted permission from our partners.